BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 30914334)

  • 21. Greater extent of prostate inflammation in negative biopsies is associated with lower risk of prostate cancer on repeat biopsy: results from the REDUCE study.
    Moreira DM; Nickel JC; Andriole GL; Castro-Santamaria R; Freedland SJ
    Prostate Cancer Prostatic Dis; 2016 Jun; 19(2):180-4. PubMed ID: 26782712
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extent of Baseline Prostate Atrophy Is Associated With Lower Incidence of Low- and High-grade Prostate Cancer on Repeat Biopsy.
    Freitas DM; Andriole GL; Castro-Santamaria R; Freedland SJ; Moreira DM
    Urology; 2017 May; 103():161-166. PubMed ID: 28024967
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of histological prostatitis in men with benign prostatic hyperplasia or adenocarcinoma of the prostate presenting without urinary retention.
    Edlin RS; Heyns CF; Van Vuuren SP; Zarrabi AD
    S Afr J Surg; 2012 Nov; 50(4):127-30. PubMed ID: 23217554
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Examination of the relationship between symptoms of prostatitis and histological inflammation: baseline data from the REDUCE chemoprevention trial.
    Nickel JC; Roehrborn CG; O'leary MP; Bostwick DG; Somerville MC; Rittmaster RS
    J Urol; 2007 Sep; 178(3 Pt 1):896-900; discussion 900-1. PubMed ID: 17632164
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study.
    Toren P; Margel D; Kulkarni G; Finelli A; Zlotta A; Fleshner N
    BMJ; 2013 Apr; 346():f2109. PubMed ID: 23587564
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Significance of histological prostatitis in patients with urinary retention and underlying benign prostatic hyperplasia or adenocarcinoma of the prostate.
    van Vuuren SP; Heyns CF; Zarrabi AD
    BJU Int; 2012 Apr; 109(8):1194-7. PubMed ID: 21851551
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inflammation is a target of medical treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia.
    De Nunzio C; Salonia A; Gacci M; Ficarra V
    World J Urol; 2020 Nov; 38(11):2771-2779. PubMed ID: 32060633
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Appearance of High Endothelial Venule-Like Vessels in Benign Prostatic Hyperplasia is Associated With Lower Urinary tract Symptoms.
    Inamura S; Shinagawa T; Hoshino H; Sakai Y; Imamura Y; Yokoyama O; Kobayashi M
    Prostate; 2017 May; 77(7):794-802. PubMed ID: 28181681
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Benign prostatic hyperplasia (BPH) and prostatitis: prevalence of painful ejaculation in men with clinical BPH.
    Nickel JC; Elhilali M; Vallancien G;
    BJU Int; 2005 Mar; 95(4):571-4. PubMed ID: 15705082
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; DamiĆ£o R; Major-Walker K; Nandy I; Morrill BB; Gagnier RP; Montorsi F;
    Eur Urol; 2010 Jan; 57(1):123-31. PubMed ID: 19825505
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of inflammation in lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and its potential impact on medical therapy.
    Ficarra V; Rossanese M; Zazzara M; Giannarini G; Abbinante M; Bartoletti R; Mirone V; Scaglione F
    Curr Urol Rep; 2014 Dec; 15(12):463. PubMed ID: 25312251
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patterns of Benign Prostate Hyperplasia Based on Magnetic Resonance Imaging Are Correlated With Lower Urinary Tract Symptoms and Continence in Men Undergoing a Robot-assisted Radical Prostatectomy for Prostate Cancer.
    Grivas N; van der Roest R; Tillier C; Schouten D; van Muilekom E; Schoots I; van der Poel H; Heijmink S
    Urology; 2017 Sep; 107():196-201. PubMed ID: 28601562
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fluctuation in prostate cancer gene 3 (PCA3) score in men undergoing first or repeat prostate biopsies.
    De Luca S; Passera R; Cappia S; Bollito E; Randone DF; Milillo A; Papotti M; Porpiglia F
    BJU Int; 2014 Dec; 114(6b):E56-E61. PubMed ID: 24472071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Efficacy of 5-reductase inhibitors in the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia].
    Nizov AN
    Urologiia; 2019 Dec; (5):156-160. PubMed ID: 31808653
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Obesity is associated with increased prostate growth and attenuated prostate volume reduction by dutasteride.
    Muller RL; Gerber L; Moreira DM; Andriole G; Hamilton RJ; Fleshner N; Parsons JK; Freedland SJ
    Eur Urol; 2013 Jun; 63(6):1115-21. PubMed ID: 23541458
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
    Roehrborn CG; Barkin J; Siami P; Tubaro A; Wilson TH; Morrill BB; Gagnier RP
    BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical effects and economical impact of dutasteride and finasteride therapy in Italian men with LUTS.
    Cindolo L; Berardinelli F; Fanizza C; Romero M; Pirozzi L; Tamburro FR; Pellegrini F; Neri F; Pitrelli A; Schips L
    Arch Ital Urol Androl; 2013 Dec; 85(4):200-6. PubMed ID: 24399122
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effects of dutasteride and finasteride on BPH-related hospitalization, surgery and prostate cancer diagnosis: a record-linkage analysis.
    Cindolo L; Fanizza C; Romero M; Pirozzi L; Autorino R; Berardinelli F; Schips L
    World J Urol; 2013 Jun; 31(3):665-71. PubMed ID: 23239103
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: guidelines of the LUTS committee of the French Urological Association].
    Descazeaud A; Robert G; Delongchamps NB; Cornu JN; Saussine C; Haillot O; Devonec M; Fourmarier M; Ballereau C; Lukacs B; Dumonceau O; Azzouzi AR; Faix A; Desgrandchamps F; de la Taille A;
    Prog Urol; 2012 Dec; 22(16):977-88. PubMed ID: 23178093
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction.
    Gratzke C; Bachmann A; Descazeaud A; Drake MJ; Madersbacher S; Mamoulakis C; Oelke M; Tikkinen KAO; Gravas S
    Eur Urol; 2015 Jun; 67(6):1099-1109. PubMed ID: 25613154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.